Intelligence:

Briefs

Home / Intelligence / Briefs

Search

Patient Journey: A New Approach To Meet The Demands Of Patient Centricity

Patient Journey is a mainstay of pre-launch commercial insights generation, traditionally sitting beside demand estimation, segmentation and other key inputs to commercial decision-making and launch preparation. Historically, Patient Journey has been used to identify leverage points and opportunities to increase market share for the new product. It has been generated through primary market research (largely qualitative) and presented as a one-time, standalone deliverable. Today, the call to engage on a meaningful level with patients demands a new focus on the…

Read Now

Capitalizing on Opportunities to Drive Impact in Commercial Operations

Throughout the first half of 2022, we’ve continued to face historic, unprecedented challenges related to the ongoing global pandemic. Life sciences enterprises, and essentially all industries, are grappling with decisions large and small. Priorities for Commercial, Market Access and Medical Affairs organizations in the life sciences industry continue to shift as teams work feverishly to evolve virtual and digital channels to engage with customers, and to sharpen Advanced Analytics. Developing capabilities and skills in new ways of working continue in…

Read Now

Patient Centricity: Optimizing Integration throughout the Lifecycle

While the vision and goal of patient centricity are clear, today’s leading life science companies are grappling with the complexities of execution: How to take the “idea” of patient centricity and translate it into strategy and tactics – and how to measure results. Read our new advisory brief to learn more about our model and the concrete actions companies can do to integrate patient centricity into their business decisions. Complete the form below to access the full brief…

Read Now

Annual State of Learning and Development in Life Sciences

Learning and Development leaders within life sciences have led and managed change like never before. The global pandemic brought live customer engagements to a halt and an intense focus on using time for enhanced development. To deliver, Learning and Development (L&D) teams had to identify resources to meet the expectations of stakeholders while redesigning and virtually-delivering to learners. In most scenarios, L&D teams were learning at the same time as their audiences. This study assesses the current landscape of L&D,…

Read Now

A Playbook for Optimizing Your Commercial Data Environment

What is keeping commercial data leaders in emerging life sciences companies up at night as they bring their technology to life in preparation for launch? What are the biggest concerns when considering changes to an existing infrastructure? Trinity Life Sciences has partnered with many first launch and emerging companies for decades to find solutions to their biggest technology challenges. In this Advisory Brief, we pause to reflect upon some of the common missteps we’ve seen companies take when deploying their…

Read Now

TGaS Advisors – What You Need To Know Now to Be Prepared for 2022

Throughout 2021, we’ve continued to face historic, massive challenges related to the ongoing global pandemic. Life sciences enterprises, and essentially all industries, grappled with decisions large and small. Priorities for Commercial and Medical Affairs organizations in the life sciences industry shifted as you worked feverishly to evolve virtual and digital channels to engage with customers as well as internal teams. Developing capabilities and skills in new ways of working came to the forefront, along with new challenges related to vaccinations…

Read Now

Digital Competency Report

Our new annual Digital Competency Report assesses 124 in-market biopharma patient brands through the lens of digital execution. The novel study evaluates the brands across five categories and 40 unique metrics to rank each one on a scale from Transformational to Novice. The excerpt, available to the public, offers a look into the rankings. TGaS Omnichannel Solution Members will receive a full report readout that dives into performance by company and therapy, cross data analysis looking at things like spend…

Read Now

Sixty-two Percent of Biopharma Executives Say Their Organization Does Not Prioritize Diversity, Equity and Inclusion When Selecting a Vendor

Waltham, MA, July 29, 2021 — Trinity Life Sciences, a leader in global life sciences commercialization solutions, is sharing findings from its latest TGaS Advisors’ report entitled Diversity, Equity, and Inclusion (DEI): An Emerging, Key Consideration When Selecting Vendors. The report finds that 62 percent of biopharma executives say their organization does not prioritize DEI as one of the top three important reasons in selecting a vendor. However, nearly half of all respondents (48 percent) indicate that DEI has increased…

Read Now

Changes in Third-Party Cookie Management and Their Effects on Pharmaceutical Brands

The elimination of third-party cookies is not a new concept. Safari and FireFox eliminated them a few years back. However, now the largest used browser (Chrome) is joining FireFox and Safari, announcing the imminent removal of third-party cookies in 2022. Organizations are attempting to navigate the impact and identify alternatives. Driven by increased user privacy, Google’s decision will require fundamental changes across media and advertising platforms. The departure of third-party cookies will change the way pharmaceutical companies, in fact all…

Read Now

Transforming the Commercial Model in the Age of COVID-19

As the year began, we couldn’t have foreseen the unprecedented impact the COVID-19 pandemic would have on US and Global enterprises. By mid-March, we were in lock-down, and priorities for Commercial and Medical Affairs organizations in the life sciences industry shifted. Leaders were working feverishly to enable virtual and digital channels to engage with customers as well as internal teams. Companies reached out to TGaS Advisors for our guidance in navigating this uncharted territory, and we stepped up to proactively…

Read Now